Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,579,921
  • Shares Outstanding, K 30,055
  • Annual Sales, $ 53,590 K
  • Annual Income, $ -80,550 K
  • 60-Month Beta 2.46
  • Price/Sales 49.02
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.12
  • Number of Estimates 4
  • High Estimate -1.10
  • Low Estimate -1.14
  • Prior Year -1.04
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.64 +7.79%
on 06/14/19
95.38 -10.00%
on 05/30/19
-1.72 (-1.96%)
since 05/24/19
3-Month
75.12 +14.27%
on 04/17/19
95.38 -10.00%
on 05/30/19
-1.29 (-1.48%)
since 03/22/19
52-Week
33.39 +157.08%
on 06/25/18
104.53 -17.88%
on 03/05/19
+48.36 (+129.03%)
since 06/22/18

Most Recent Stories

More News
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

RETA : 85.84 (-1.80%)
MRUS : 14.09 (-1.19%)
RGEN : 81.91 (-1.36%)
ACOR : 7.40 (-1.20%)
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone...

RETA : 85.84 (-1.80%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

RETA : 85.84 (-1.80%)
Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs

Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019

RETA : 85.84 (-1.80%)
Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that Colin Meyer, M.D., Reata's Chief Medical Officer, will present a talk entitled "Translating...

RETA : 85.84 (-1.80%)
Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 85.84 (-1.80%)
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results

PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019

RETA : 85.84 (-1.80%)
Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RETA : 85.84 (-1.80%)
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 85.84 (-1.80%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade RETA with:

Business Summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address...

See More

Key Turning Points

2nd Resistance Point 89.79
1st Resistance Point 87.81
Last Price 85.84
1st Support Level 84.43
2nd Support Level 83.03

See More

52-Week High 104.53
Last Price 85.84
Fibonacci 61.8% 77.35
Fibonacci 50% 68.96
Fibonacci 38.2% 60.57
52-Week Low 33.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar